Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience

Journal of the American College of Cardiology

Volumn 43, Issue 11, 2004, Pages 1973-1981

  Benza, Raymond L ^a   Zoghbi, Gilbert J ^a   Tallaj, Jose ^a,b   Brown, Robert ^c   Kirklin, James K ^c   Hubbard, Meloneysa ^a   Rayburn, Barry ^a   Foley, Brian ^a   McGiffin, David C ^c   Pinderski, Laura J ^a   Misra, Vijay ^a   Bourge, Robert C ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c Kentucky   (United States)

Author keywords

ACD; allograft coronary disease; anti proliferative; AP; CAD; coronary artery disease; minimal luminal diameter; MLD; MMF; mycophenolate mofetil; PCI; percutaneous coronary intervention; percutaneous transluminal coronary angioplasty; PTCA

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALLOGRAFT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; SURVIVAL; VASCULAR DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 2542447364     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.02.045     Document Type: Article

References (39)

1. Costanzo M.R., Naftel D.C., Pritzel M.R., et al. Heart transplant coronary artery disease detected by coronary angiography A multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 17:1992;744-753
2. Boehmer J.P., Brown R.N., Leier C.V., et al. Advanced allograft coronary artery disease Interaction between pre- and post-transplant risk factors from a ten-year multi-institutional study (abstr). J Heart Lung Transplant. 21:2002;19
3. Keogh A., Valantine H., Hunt S., et al. Impact of proximal or mid-vessel discreet coronary artery stenosis on survival after heart transplantation. J Heart Lung Transplant. 11:1992;892-901
4. Halle A.A., DiSciacio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 26:1995;120-128
5. Heublein B., Pethig K., Maas C., Wahlers T., Haverlich A. Coronary artery stenting in cardiac allograft vascular disease. J Am Coll Cardiol. 32:1997;1636-1640
6. Jain S.P., Ramee S.R., White C.J., et al. Coronary stenting in cardiac allograft vasculopathy. J Am Coll Cardiol. 32:1998;1636-1640
7. Swan J.W., Norell M., Yacoub M., Mitchell A.G., Ilsley C. Coronary angioplasty in cardiac transplant recipients. Eur Heart J. 14:1993;65-70
8. Von Scheidt W., Uberfuhr P., Reichart B., Steinbeck G. The role of PTCA in the management of focal critical lesions in transplant coronary artery disease. Transplant Proc. 27:1995;1936-1938
9. Schnetzler B., Drobinski G., Dorent R., et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant. 19:2000;557-565
10. Sharifi M., Siraj Y., O'Donnell J., Pompili V.J. Coronary angioplasty and stenting in orthotopic heart transplants A fruitful act or a futile attempt? Angiology. 51:2000;809-815
11. Blackstone E.H., Naftel D.C., Turner M.E. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc. 81:1986;615-624
12. Sandhu J.S., Uretsky B.F., Reddy P.S., et al. Potential limitations of percutaneous transluminal coronary angioplasty in heart transplant recipients. Am J Cardiol. 69:1992;1234-1237
13. Christensen B.V., Meyer S.M., Iacarella C.L., Kubo S.H., Wilson R.F. Coronary angioplasty in heart transplant recipients A quantitative angiographic long-term follow-up study. J Heart Lung Transplant. 13:1994;212-220
14. Mullins P.A., Shapiro L.M., Aravot D.A., et al. Experience of percutaneous transluminal coronary angioplasty in orthotopic cardiac transplant recipients. Eur Heart J. 12:1991;1205-1207
15. Wong P.M., Piamsomboon C., Mathur A., et al. Efficacy of coronary stenting in the management of cardiac allograft vasculopathy. Am J Cardiol. 82:1988;239-241
16. Redonnet M., Tron C., Koning R., et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant Proc. 32:2000;463-465
17. the ACC/AHA Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty), Smith S.C. Jr., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary A report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the society for cardiac angiography and interventions. Circulation. 103:2001;3019-3041
18. Al Suwaidi J., Berger P.B., Holmes D.R. Jr. Coronary artery stents. JAMA. 284:2000;1828-1836
19. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty A serial intravascular ultrasound study. Circulation. 94:1996;35-43
20. Williams D.O., Holubkov R., Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-1986 The national heart, lung, and blood institute registries. Circulation. 102:2000;2945-2951
21. McGrath P.D., Malenka D.J., Wennberg D.E., et al. Changing outcomes in percutaneous coronary interventions A study of 34, 752 procedures in northern new england, 1990 to 1997: northern new england cardiovascular disease study group. J Am Coll Cardiol. 34:1999;674-680
22. Rankin J.M., Spinelli J.J., Carere R.G., et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 341:1999;1957-1965
23. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease Stent restenosis study investigators. N Engl J Med. 331:1994;496-501
24. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease Benestent study group. N Engl J Med. 331:1994;489-495
25. Rothman M., Serruys P., Grollier G., et al. Angiographic and clinical one-year follow-up of the Cordis tantalum coil stent in a multicenter international study demonstrating improved restenosis rates when compared to pooled PTCA and BENESTENT-I data The European Antiplatelet Stent Investigation (EASI). Cathet Cardiovasc Intervent. 52:2001;249-259
26. Peterson E.D., Lansky A.J., Anstrom K.J., et al. Evolving trends in interventional device use and outcomes Results from the national cardiovascular network database. Am Heart J. 139:2000;198-207
27. Weintraub W.S., Mahoney E.M., Ghazzal Z.M., et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol. 88:2001;497-503
28. Laskey W.K., Kimmel S., Krone R.J. Contemporary trends in coronary intervention A report from the Registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Intervent. 49:2000;19-22
29. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961
30. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary stents. N Engl J Med. 334:1996;1084-1089
31. Mehra M.R., Ventura H.O., Chambers R., et al. Predictive model to assess risk for cardiac allograft vasculopathy An intravascular ultrasound study. J Am Coll Cardiol. 26:1995;1537-1544
32. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493
33. Katznelson S., Wang X.M., Chia D., et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 17:1998;335-340
34. Maggard M.A., Ke B., Wang T., et al. Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation. 65:1998;149-155
35. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627
36. Moon J.I., Kim Y.S., Kim M.S., et al. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells In vitro study. Transplant Proc. 32:2000;2026-2027
37. Batchelor W.B., Robinson R., Strauss B.H. The extracellular matrix in balloon arterial injury. Prog Cardiovasc Dis. 41:1998;35-49
38. Kobashigawa J., Miller L., Eisen H., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 66:1998;507-515
39. Greenstein S.M., Sun S., Calderon T.M., et al. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J Surg Res. 91:2000;123-129